Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

导出原文传递

翻译打印收藏纠错

作者： Rini, Brian I. ^[1] ; Pal, Sumanta K. ^[2] ; Escudier, Bernard J. ^[3] ; Atkins, Michael B. ^[4] ; Hutson, Thomas E. ^[5] ; Porta, Camillo ^[6] ; Verzoni, Elena ^[7] ; Needle, Michael N. ^[8] ; McDermott, David F. ^[9]

作者单位： Baylor Sammons Canc Ctr Texas Oncol, Urol Oncol, Dallas, TX USA ^[1] City Hope Natl Med Ctr, Kidney Canc Program, 1500 E Duarte Rd, Duarte, CA 91010 USA ^[2] Cleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH 44106 USA ^[3] Georgetown Lombardi Univ Hosp, Lombardi Comprehens Canc Ctr, Dept Med Oncol, Washington, DC USA ^[4] Gustave Roussy Canc Campus, Dept Med Oncol, Villejuif, France ^[5] Univ Pavia, Dept Internal Med, Pavia, Italy ^[6] AVEO Oncol, Cambridge, MA USA ^[7] Beth Israel Deaconess Med Ctr, Dept Hematol Oncol, Boston, MA 02215 USA ^[8] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy ^[9]

发布时间 2020-06-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The lancet oncology

2020年21卷1期

95-104页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

The lancet oncology

相似文献

The lancet oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

The lancet oncology

相似文献

The lancet oncology

相关期刊

检索历史清除